Tag Archives: Vaccine

Factbox-Latest on the worldwide spread of the coronavirus

(Reuters) – The Tokyo Paralympics will take place generally without spectators, organizers said, as the government was set to prolong COVID-19 emergency measures in the capital and other regions that will run through the Games.

EUROPE

* The European Guarantee Fund, which is managed by the Investment Bank Group, secured European Union approval to provide guarantees on synthetic securitization tranches to help companies in 22 EU countries affected by the pandemic.

* Poland will send 650,000 doses of the AstraZeneca vaccine to Ukraine, the minister in charge of the Polish vaccination drive told state news agency PAP.

* North Macedonia has reimposed restrictions on access to cafes, restaurants and public events in a bid to subdue a fresh spike in infections and nudge citizens to get vaccinated, prompting public anger and protests.

* All 16- and 17-year-olds in England will be offered their first vaccine dose by Aug. 23, according to a target set by British Health Secretary Sajid Javid.

ASIA-PACIFIC

* Thailand, a regional manufacturer of AstraZeneca’s coronavirus shots, is seeking to borrow 150,000 doses of the same vaccine from the Himalayan kingdom of Bhutan, an official said, amid a Thai supply shortage.

* Indonesia extended its curbs though relaxed some measures in eight unspecified areas on the most populous islands of Java and Bali, as fewer infections have been reported in cities.

* Hong Kong’s government said it would upgrade 15 overseas places including the United States, Spain and France to “high risk” from “medium risk” by Aug. 20, meaning international arrivals from those countries will face lengthened quarantine due to a resurgence of the coronavirus.

* Taiwan has rejected an application for the emergency use of UBI Pharma’s vaccine candidate, the government said.

AMERICAS

* As the Delta variant of the virus sweeps through Mexico’s cities, more adults in their 30s and 40s are ending up in the hospital with polls showing vaccine hesitancy is rising in younger age groups.

MIDDLE EAST AND AFRICA

* Turkey is allowing people who were inoculated with Sinovac’s coronavirus vaccine to take an additional Pfizer dose as it looks to ease travel to countries that have not approved the Chinese shot, the health ministry said.

MEDICAL DEVELOPMENTS

* Europe’s drugs regulator said it was evaluating the use of Roche’s arthritis drug, Actemra, in hospitalized adults with severe COVID-19, its latest review of a potential coronavirus treatment.

* The UK’s health regulator said coronavirus vaccines did not raise the risk of miscarriage, and that it had not found any link between the shots and changes to menstrual periods.

* GlaxoSmithKline and CureVac said a study on macaque monkeys showed their jointly-developed vaccine candidate to be “strongly improved” in protecting against the virus compared with CureVac’s first attempt.

ECONOMIC IMPACT

* A surprisingly sharp slowdown in Chinese economic activity and a rapid Taliban takeover in Afghanistan helped drive global shares lower Monday.

* The initial success of Israel’s COVID-19 vaccination rollout that enabled an opening of the economy bolstered growth in the second quarter, official figures showed.

* Thailand’s economy unexpectedly grew in the second quarter from the first helped by exports and government spending, but spiking cases continue to batter domestic activity and tourism, restraining its fragile recovery.

(Compiled by Veronica Snoj and Federico Maccioni; Edited by Shounak Dasgupta)

WHO’s pandemic project faces cash crunch amid vaccine, oxygen shortages

By Francesco Guarascio

BRUSSELS (Reuters) – The World Health Organization (WHO) is seeking $11.5 billion in urgent funding to fight the more infectious Delta variant of the coronavirus, a draft report seen by Reuters shows, amid worries wealthy nations are partly bypassing its COVID-19 programs.

A large portion of the cash being requested from the WHO’s partners is needed to buy tests, oxygen and face masks in poorer nations, says the document which is expected to be released this week. And a quarter of it would be to buy hundreds of millions of vaccines for them that would otherwise go elsewhere.

The paper, still subject to changes, outlines the results and financial needs of the Access to COVID-19 Tools Accelerator (ACT-A), the program co-led by the WHO to distribute fairly COVID-19 vaccines, drugs and tests across the world.

The program, set up at the start of the pandemic, remains vastly underfunded, and its coordinators are now acknowledging it will remain so as many governments look to address global COVID needs “differently,” an ACT-A official told Reuters, speaking on condition of anonymity.

As a result, it has cut by nearly $5 billion its total request for funds, the document shows. But it still needs $16.8 billion, almost as much as what has been raised so far, and $7.7 billion is required urgently.

The document also calls for a further $3.8 billion, on top of the $7.7 billion, to take up options for 760 million doses of COVID-19 vaccines that would be delivered next year.

“These options to buy need to be exercised in the coming months or vaccine doses will be lost,” the document warns.

WHO Director-General Tedros Adhanom Ghebreyesus last week said that $7.7 billion were urgently needed, but did not give a breakdown of planned spending, and did not say how much extra money was needed for vaccines.

The WHO was not immediately available to comment.

The latest cash crunch will underscore concerns about the long-term future of the program, which has struggled to secure supplies and equipment to tame a pandemic that has killed more than 4.2 million.

The vaccine portion of the project, called COVAX, is increasingly reliant on donations from wealthy nations, rather than its own supplies, after key manufacturer India restricted exports of shots to boost domestic vaccinations.

But the United States, European Union and Japan have also donated vaccines directly to countries as part of their vaccine diplomacy drives. Japan has also said it’s a quicker process than going through COVAX.

Some countries have provided equipment directly to others too. Last month, Australia said it would donate oxygen-related equipment, antigen test-kits as well as vaccines to Indonesia.

The plea for cash comes as a review of the ACT-A gets under way, with France, Germany and Canada among the countries steering the process. A report on the program’s results and shortcomings is expected in September by consultancy Dalberg Global Development Advisors, the ACT-A official said.

OXYGEN NEEDS

Among ACT-A’s immediate needs are $1.2 billion for oxygen to treat seriously ill COVID-19 patients in poorer countries where supplies are low, the report says.

Oxygen has moved up the priority list given vaccines are not available, the ACT-A official said, highlighting the repercussions from the shortage of shots as the Delta variant spreads to 132 countries.

COVAX has delivered about 180 million vaccines, far short of its 2 billion target by the end of this year.

Oxygen is needed to “control the exponential death surges caused by the Delta variant,” the document says.

Global demand for medical oxygen is currently more than a dozen times greater than before the pandemic, the document says, but many countries are struggling to access sufficient supplies.

The urgent need for the most basic treatment against COVID-19 one and a half years into the pandemic shows how little has been done to combat the virus in most of the world, the ACT-A official said, noting: “There hasn’t been much progress. What was urgent three months ago is still urgent now.”

“Inequity in access to life-saving COVID-19 tools has never been more apparent,” the document says.

In rich nations, most people have already been vaccinated, including the younger who are less at risk from COVID-19, whereas in poorer nations the most vulnerable are still waiting for a first dose and there is a lack of basic materials, such as face masks and other personal protective equipment (PPE).

“Avoidable death and unsustainable pressure on health systems is mounting in many countries due to insufficient access to oxygen and PPE,” the document says.

At least $1.7 billion are urgently needed to buy protective devices for healthcare workers in poorer nations, the document says, and another $2.4 billion are needed to boost testing in low-income countries.

(Reporting by Francesco Guarascio @fraguarascio; Editing by Josephine Mason and Mark Potter)

Britain’s COVID-19 cases up by nearly 41% over past week

LONDON (Reuters) – Britain has reported 46,558 new cases of COVID-19, government data showed on Tuesday, meaning the rise in cases between July 14 and July 20 stood at 40.7% compared with the previous seven days.

A further 96 people were reported as having died within 28 days of a positive test for COVID-19.

A total of 46.35 million people had received a first dose of a vaccine against coronavirus by July 19 and 36.24 million people had received a second dose.

(Writing by William Schomberg)

Living with COVID-19: Israel changes strategy as Delta variant hits

By Maayan Lubell

JERUSALEM (Reuters) – Four weeks ago, Israel was celebrating a return to normal life in its battle with COVID-19.

After a rapid vaccination drive that had driven down coronavirus infections and deaths, Israelis had stopped wearing face masks and abandoned all social-distancing rules.

Then came the more infectious Delta variant, and a surge in cases that has forced Prime Minister Naftali Bennett to reimpose some COVID-19 restrictions and rethink strategy.

Under what he calls a policy of “soft suppression,” the government wants Israelis to learn to live with the virus – involving the fewest possible restrictions and avoiding a fourth national lockdown that could do further harm to the economy.

As most Israelis in risk groups have now been vaccinated against COVID-19, Bennett is counting on fewer people than before falling seriously ill when infections rise.

“Implementing the strategy will entail taking certain risks but in the overall consideration, including economic factors, this is the necessary balance,” Bennett said last week.

The main indicator guiding the move is the number of severe COVID-19 cases in hospital, currently around 45. Implementation will entail monitoring infections, encouraging vaccinations, rapid testing and information campaigns about face masks.

The strategy has drawn comparisons with the British government’s plans to reopen England’s economy from lockdown, though Israel is in the process of reinstating some curbs while London is lifting restrictions.

The curbs that have been reinstated include the mandatory wearing of face masks indoors and quarantine for all people arriving in Israel.

Bennett’s strategy, like that of the British government, has been questioned by some scientists.

Israel’s Health Ministry advocates more of a push for stemming infections, Sharon Alroy-Preis, head of public health at Israel’s Health Ministry, told Kan Radio on Sunday.

“It’s possible that there won’t be a big rise in the severely ill but the price of making such a mistake is what’s worrying us,” she said.

But many other scientists are supportive.

“I am very much in favor of Israel’s approach,” said Nadav Davidovitch, director of the school of public health at Israel’s Ben Gurion University, describing it as a “golden path” between Britain’s easing of restrictions and countries such as Australia that take a tougher line.

THE VIRUS ‘WON’T STOP’

Israel’s last lockdown was enforced in December, about a week after the start of what has been one of the world’s fastest vaccination programs.

New daily COVID-19 infections are running at about 450. The Delta variant, first identified in India, now makes up about 90% of cases.

“We estimate that we won’t reach high waves of severe cases like in previous waves,” the health ministry’s director-general, Nachman Ash, said last week. “But if we see that the number and increase rate of severe cases are endangering the (health) system, then we will have to take further steps.”

Around 60% of Israel’s 9.3 million population have received at least one shot of the Pfizer/BioNtech vaccine. On Sunday, the government began offering a third shot to people with a compromised immune system.

Ran Balicer, chair of the government’s expert panel on COVID-19, said Israel had on average had about five severe cases of the virus and one death per day in the last week, after two weeks of zero deaths related to COVID-19.

Noting the impact of the Delta variant, he said the panel was advising caution over the removal of restrictions.

“We do not have enough data from our local outbreak to be able to predict with accuracy what would happen if we let go,” Balicer said.

Some studies have shown that though high, the Pfizer/BioNTech vaccine’s effectiveness against the Delta variant is lower than against other coronavirus strains.

Drawing criticism from some scientists, Pfizer and BioNTech SE have said they will ask U.S. and European regulators to authorize booster shots to head off increased risk of infection six months after inoculation.

Israel is in no rush to approve public booster shots, saying there is no unequivocal data yet showing they are necessary. It is offering approval only to people with weak immune systems on a case-by-case basis.

Authorities are also considering allowing children under 12 to take the vaccine on a case-by-case basis if they suffer from health conditions that put them at high risk of serious complications if they were to catch the virus.

Only “a few hundred” of the 5.5 million people who have been vaccinated in Israel have later been infected with COVID-19, Ash said.

Before the Delta variant arrived, Israel had estimated 75% of the population would need to be vaccinated to reach “herd immunity” – the level at which enough of a population are immunized to be able to effectively stop a disease spreading. The estimated threshold is now 80%.

Such data ensure doctors remain concerned.

“…the virus won’t stop. It is evolving, it’s its nature. But our nature is to survive,” said Dr. Gadi Segal, head of the coronavirus ward at Sheba Medical Centre near Tel Aviv.

(Writing by Maayan Lubell; Editing by Jeffrey Heller and Timothy Heritage)

‘Be cautious’: Johnson goes ahead with lifting England’s COVID curbs

By Costas Pitas and Alistair Smout

LONDON (Reuters) -British Prime Minister Boris Johnson urged people on Monday to show caution when nearly all remaining COVID-19 restrictions are lifted in England next week, saying an increase in cases underlined that the pandemic was by no means over.

England will from July 19 be the first nation in Britain to lift the legal requirement to wear masks and for people to socially distance. The government says Britain’s vaccination drive – one of the world’s fastest – has largely broken the link between infections and serious illness or death.

But what was once billed as “freedom day” is now being treated with wariness by ministers after a new surge in cases and fears that there could be as many as 100,000 new infections a day over the summer.

Johnson set a somber tone, defending his decision to lift most of the remaining restrictions by saying the four conditions the government set itself had been met, but also warning the country that more people would die from the coronavirus.

“We think now is the right moment to proceed…But it is absolutely vital that we proceed now with caution and I cannot say this powerfully or emphatically enough – this pandemic is not over,” he told a press conference.

“To take these steps we must be cautious and must be vaccinated,” he said, adding that England would see “more hospitalizations and more deaths from COVID”.

Johnson added: “I generally urge everyone to keep thinking of others and to consider the risks.”

Earlier, health minister Sajid Javid told parliament that people should still wear masks in crowded areas like on public transport and should only gradually move back to the workplace, and that the government would encourage businesses holding mass events to use health certification as a way to open up.

Business welcomed the move, but also called on the government to offer clearer guidance. Claire Walker, co-executive director of the British Chambers of Commerce, said companies still did not have the full picture they needed.

“Business leaders aren’t public health experts and cannot be expected to know how best to operate when confusing and sometimes contradictory advice is coming from official sources,” she said.

GLOBAL STRUGGLE

After 18 months of pandemic, governments around the world have been wrestling with how and when to reopen their economies.

Dutch Prime Minister Mark Rutte conceded on Monday that coronavirus restrictions had been lifted in the Netherlands too soon and he apologized as infections surged to their highest levels of the year.

Britain has implemented one of the world’s swiftest vaccination programs, with more than 87% of adults having received at least one dose of a COVID-19 vaccine and 66% having received two.

The Conservative government argues that the fact that deaths and hospital admissions remain far lower than before, even though cases have risen sharply, is proof that the vaccines are saving lives and it is now safer to open up.

But the surge in infections to rates unseen since the winter has raised concern, with some epidemiologists saying the Euro soccer championships might have helped fuel the rise.

Britain, which ranks 20th in the world for per-capita reported deaths from COVID-19, on Monday reported a further 34,471 COVID-19 cases, up 26% in a week, and six additional deaths within 28 days of a positive test.

London’s Wembley Stadium hosted the Euro 2020 final on Sunday between England and Italy. Large crowds gathered in London, including around the stadium, and there were reports that some had gained entry to the match without tickets to join the more than 60,000 who had them – much to the dismay of the World Health Organization.

“Am I supposed to be enjoying watching transmission happening in front of my eyes?” WHO epidemiologist Maria Van Kerkhove tweeted in the late stages of the match.

“The #COVID19 pandemic is not taking a break tonight … #SARSCoV2 #DeltaVariant will take advantage of unvaccinated people, in crowded settings, unmasked, screaming/shouting/singing. Devastating.”

(Additional reporting by Elizabeth Piper, William James and Michael Holden in London, Emma Farge in Geneva; Editing by Nick Macfie and Mark Heinrich)

Heart inflammation after COVID-19 shots higher-than-expected in study of U.S. military

By Carl O’Donnell

(Reuters) – Members of the U.S. military who were vaccinated against COVID-19 showed higher-than-expected rates of heart inflammation, although the condition was still extremely rare, according to a study released on Tuesday.

The study found that 23 previously healthy males with an average age of 25 complained of chest pain within four days of receiving a COVID-19 shot. The incident rate was higher than some previous estimates would have anticipated, it said.

All the patients, who at the time of the study’s publication had recovered or were recovering from myocarditis – an inflammation of the heart muscle – had received shots made by either Pfizer Inc and BioNTech SE or Moderna Inc.

U.S. health regulators last week added a warning to the literature that accompanies those mRNA vaccines to flag the rare risk of heart inflammation seen primarily in young males. But they said the benefit of the shots in preventing COVID-19 clearly continues to outweigh the risk.

The study, which was published in the JAMA Cardiology medical journal, said 19 of the patients were current military members who had received their second vaccine dose. The others had either received one dose or were retired from the military.

General population estimates would have predicted eight or fewer cases of myocarditis from the 436,000 male military members who received two COVID-19 shots, the study said.

An outside panel of experts advising the U.S. Centers for Disease Control and Prevention (CDC) said last week that reports of myocarditis were higher in males and in the week after the second vaccine dose than would be anticipated in the general population. A presentation at that meeting found the heart condition turned up at a rate of about 12.6 cases per million people vaccinated.

Eight of the military patients in the study were given diagnostic scans and showed signs of heart inflammation that could not be explained by other causes, the study said. The patients in the study ranged from ages 20 to 51.

The CDC began investigating the potential link between the mRNA vaccines and myocarditis in April after Israel flagged that it was studying such cases in people who received the Pfizer/BioNTech vaccine there, and after a report that the U.S. military had also found cases.

Health regulators in several countries are conducting their own investigations.

(Reporting by Carl O’Donnell; Editing by Bill Berkrot)

Pandemic tied to spike in diabetes in children; type of immune response lasts months after Pfizer/BioNTech vaccine

By Nancy Lapid

(Reuters) – The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Pandemic tied to sharp rise in type 2 diabetes in kids

Hospitalization rates for children with newly diagnosed type 2 diabetes more than doubled during the pandemic, two hospitals reported at the American Diabetes Association Scientific Sessions, held virtually this year. At Our Lady of the Lake Children’s Hospital in Baton Rouge, Louisiana, children with newly diagnosed type 2 diabetes accounted for 0.62% of inpatients from March through December 2020, up from 0.27% the year before. Those numbers are low, “but just the fact that this rate has more than doubled over the past year is … significant,” said Dr. Daniel Hsia of Pennington Biomedical Research Center in Baton Rouge. Children hospitalized in 2020 had more severe diabetes, with higher blood sugar and more dehydration, than children admitted in the prior year, he said. At Children’s National Hospital in Washington, DC, cases of new-onset type 2 diabetes in children increased 233% from 2019 to 2020 – and the children were sicker than in previous years, a separate team reported. Most of these children at both hospitals had not previously had COVID-19. Social distancing measures may have kept children from having regular physical activity and contributed to weight gain, and also kept parents from taking them for routine medical care, all of which may have contributed to more severe illness, researchers speculated. “Our study reinforces the importance of maintaining a healthy lifestyle for children even under such difficult circumstances” Hsia said in a statement.

Immune cell “factories” work longer after mRNA vaccines

The tiny “factories” in lymph nodes that churn out antibody-producing B cells to fight infections, called germinal centers, were still functioning to hold COVID-19 at bay for months after people received the mRNA vaccine from BioNTech and Pfizer, according to a new study. After most vaccines, germinal centers last only a few weeks. “Germinal centers are the key to a persistent, protective immune response,” said Ali Ellebedy of Washington University School of Medicine in St. Louis, who coauthored a report on Monday in Nature. “Germinal centers are where our immune memories are formed. And the longer we have a germinal center, the stronger and more durable our immunity will be because there’s a fierce selection process happening there, and only the best immune cells survive.” Researchers studied cells from germinal centers in armpit lymph nodes of 14 recipients of the Pfizer/BioNTech vaccine. Three weeks after the first dose, all 14 had germinal centers that were still generating B cells. B-cell production “expanded greatly” after the second shot and stayed high, they reported. Eight of 10 people biopsied 15 weeks after the first dose, still had functioning germinal centers. “We’re still monitoring the germinal centers, and … in some people, they’re still ongoing,” Ellebedy said. “This is truly remarkable.” The same effect is likely also true for Moderna’s mRNA vaccine, the researchers believe. Ultimately, immune cells called T cells are what sustains the germinal centers’ work after they disappear. The researchers plan next to investigate the magnitude and durability of T cell responses after mRNA COVID-19 vaccines.

Following AstraZeneca with Pfizer shot boosts antibody response

Giving a dose of the Pfizer/BioNTech COVID-19 vaccine four weeks after an AstraZeneca shot produces better immune responses than a second dose of AstraZeneca’s, Oxford University researchers said on Monday. In a study of 830 older adults, mixed two-dose schedules of AstraZeneca and Pfizer vaccines produced higher concentrations of antibodies against the coronavirus that a full schedule of the AstraZeneca shot. The most effective approach – two doses of Pfizer/BioNTech mRNA vaccine – produced levels of antibodies about 10 times higher than two doses of the AstraZeneca vaccine, the researchers reported on Friday in a Lancet preprint. However, the AstraZeneca shot followed by a Pfizer jab induced antibody levels about as high as two Pfizer/BioNTech doses. Giving the Pfizer shot first, followed by AstraZeneca’s, was not as successful. That combination yielded antibody levels higher than two AstraZeneca shots but lower than two doses of the Pfizer vaccine. There were no new safety issues uncovered in the study. Matthew Snape, the Oxford professor behind the trial, said the findings could be used to give flexibility to vaccine rollouts but were not significant enough to recommend a broad shift away from clinically approved schedules.

COVID-19, not Pfizer’s vaccine, tied to Bell’s palsy

The Pfizer/BioNTech vaccine has not been linked with a higher risk for the facial nerve paralysis known as Bell’s palsy, but COVID-19 itself does increase the risk, suggest two separate studies published on Thursday in JAMA Otolaryngology-Head and Neck Surgery. One study involved 110 people in Israel who received the Pfizer vaccine, including 37 in whom the characteristic facial droop developed on average nine days after the first dose or 14 days after the second. After accounting for underlying risk factors for Bell’s palsy, the researchers concluded the vaccine itself did not increase the risk. Furthermore, they found, rates of Bell’s palsy had not gone up during the vaccine rollout. In the second study, researchers compared Bell’s palsy rates among roughly 348,000 patients with COVID-19 and roughly 63,500 people who had been vaccinated against the coronavirus. The Bell’s palsy risk was nearly seven times higher in those with COVID-19, they found. “Our data suggest that rates of facial nerve palsy are higher in patients who are positive for COVID-19, and this incidence exceeds the reported incidence of Bell’s Palsy with the COVID-19 vaccine,” said Dr. Akina Tamaki of University Hospitals Cleveland Medical Center, who coauthored that study. “Taken together, it supports that the vaccine is safe from a facial nerve paralysis standpoint.”

(Reporting by Nancy Lapid, Megan Brooks, Marilynn Larkin and Alistair Smout; Editing by Bill Berkrot)

Delta COVID variant becoming globally dominant, WHO official says

GENEVA (Reuters) – The Delta variant of COVID-19, first identified in India, is becoming the globally dominant variant of the disease, the World Health Organization’s chief scientist said on Friday.

Soumya Swaminathan also voiced disappointment in the failure of CureVac’s vaccine candidate in a trial to meet the WHO’s efficacy standard, in particular as highly transmissible variants boost the need for new, effective shots.

Britain has reported a steep rise in infections with the Delta variant, while Germany’s top public health official predicted it would rapidly become the dominant variant there despite rising vaccination rates.

The Kremlin blamed a surge in COVID-19 cases on reluctance to have vaccinations and “nihilism” after record new infections in Moscow, mostly with the new Delta variant, fanned fears of a third wave.

“The Delta variant is well on its way to becoming the dominant variant globally because of its increased transmissibility,” Swaminathan told a news conference.

Coronavirus variants were cited by CureVac when the German company this week reported its vaccine proved only 47% effective at preventing disease, shy of the WHO’s 50% benchmark.

The company said it documented at least 13 variants circulating within its study population.

Given that similar mRNA vaccines from Pfizer and BioNTech and Moderna posted efficacy rates topping 90%, Swaminathan said the world had been expecting more from CureVac’s candidate.

“Just because it’s another mRNA vaccine, we cannot presume all mRNA vaccines are the same, because each one has a slightly different technology,” Swaminathan said, adding the surprise failure underscored the value of robust clinical trials to test new products.

WHO officials said Africa remains an area of concern, even though it accounts for only around 5% of new global infections and 2% of deaths.

New cases in Namibia, Sierra Leone, Liberia and Rwanda have doubled in the last week, WHO emergencies program head Mike Ryan said, while vaccine access remains miniscule.

“It’s a trajectory that is very, very concerning,” Ryan said. “The brutal reality is that in an era of multiple variants, with increased transmissibility, we have left vast swathes of the population, the vulnerable population of Africa, unprotected by vaccines.”

(Reporting by John Miller, writing by Giles Elgood, Editing by Catherine Evans and Michael Shields)

Factbox: Latest on the worldwide spread of the coronavirus

(Reuters) – The head of the World Health Organization has called for launching negotiations this year on an international treaty to boost pandemic preparedness, as part of sweeping reforms envisioned by member states.

EUROPE

* Germany’s Robert Koch Institute (RKI) for infectious disease is to reduce the coronavirus risk level for the country to “high” from “very high” as the situation improves, Health Minister Jens Spahn said.

* Spain is considering easing rules on wearing face masks outdoors, as early as in mid-June.

AMERICAS

* With half the country at least partially protected against the coronavirus, Americans escaped their pandemic doldrums over the Memorial Day holiday weekend.

ASIA-PACIFIC

* South Korea closed its first phase of reservations for Johnson and Johnson vaccines as military personnel signed up for all 800,000 shots on offer, the government said.

* A shipment of coronavirus vaccines to North Korea via the global COVAX sharing program that was expected for late May has been delayed again amid protracted consultations, South Korea’s Unification Ministry said.

* Australia’s Victoria state authorities said it was still unclear whether a snap one-week lockdown to contain a fresh COVID-19 outbreak would end as planned on Thursday night, as the state grapples with a growing virus outbreak.

* Japan plans to start vaccination at workplaces and universities on June 21 to speed up the country’s inoculation drive.

MIDDLE EAST AND AFRICA

* Dubai, the second-largest member of the United Arab Emirates federation, has started offering the Pfizer-BioNTech vaccine to 12-15 year old’s, the government media office said on Twitter.

* Turkey further eased measures including partially lifting a weekend lockdown and opening restaurants to a limited number of guests.

MEDICAL DEVELOPMENTS

* A Wuhan-based affiliate of China’s Sinopharm said the start of operations at a new factory will raise the annual production capacity of its COVID-19 vaccine to at least 1 billion doses.

* A deal on an intellectual property waiver for COVID-19 vaccines at the World Trade Organization was no closer to acceptance on Monday despite Washington’s backing, due to expected skepticism about a new draft, sources close to the talks told Reuters.

ECONOMIC IMPACT

* Global stocks again hit record highs and oil rose on Tuesday, before European and U.S. data that should this week offer major clues to the health of the world economy.

* Euro zone manufacturing activity expanded at a record pace in May, according to a survey which suggested growth would have been even faster without supply bottlenecks that have led to an unprecedented rise in input costs.

* Ireland will begin to gradually phase out temporary coronavirus-related jobless payments later this year while maintaining other income and business supports as the economy fully reopens, Public Expenditure Minister Michael McGrath said.

* Turkish factory activity shrank in May for the first time in a year as output and new orders slowed down due to a 17-day full lockdown imposed to curb a surge in new coronavirus cases, a survey showed.

(Compiled by Jagoda Darlak and Ramakrishnan M.; Editing by William Maclean)

Vaccine protects COVID-19 survivors against variants; virus’ spike protein damages blood vessels

By Nancy Lapid

(Reuters) – The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Vaccine protects COVID-19 survivors against variants

In COVID-19 survivors, the Pfizer/BioNTech mRNA vaccine protects not only against the original virus strain but also against worrisome variants, two studies show. UK researchers analyzed immune responses after a single dose of the vaccine in 51 people, including 25 people previously infected with an early version of the novel coronavirus. Survivors showed enhanced antibody responses against the newer, more infectious variants first seen in the UK and South Africa, whereas people who had not previously been infected did not produce antibodies that could neutralize the variants, according to a report on Friday in Science. Separately, U.S researchers studied 30 people after two doses of the vaccine. Immune responses were 3.4 times better at neutralizing the coronavirus in the 10 COVID-19 survivors than in the 20 who were not previously infected, they reported on medRxiv on Thursday ahead of peer review. The difference was even greater when looking at neutralization of new variants from the UK, South Africa and Brazil, said coauthor Fikadu Tafesse of Oregon Health & Science University. “For example, the South African variant, which is the best at evading neutralizing antibodies, was 6.5 times better blocked,” or neutralized, in blood samples from people who were vaccinated after infection, he said. “Our findings give people another reason to go out and get vaccinated even if they have already had COVID-19.”

COVID-19 spike protein damages blood vessels

The “spike” proteins that the coronavirus uses to help it break into cells inflicts other damage as well, according to a new study that shines a spotlight on the many ways COVID-19 attacks organs other than the lungs. The spike proteins themselves cause direct damage to the cells that line the blood vessels, scientists found in test tube experiments using an engineered version of the spike and artery-lining cells obtained from mice. After attaching itself to the ACE2 protein on healthy cells, the spike disrupts signaling from ACE2 to the mitochondria – the cell’s energy-generating structures – causing the mitochondria to become damaged, researchers reported on Friday in Circulation Research. COVID-19 is really a disease of the blood vessels, coauthor Uri Manor of the Salk Institute for Biological Studies in La Jolla, California said in a statement. The new findings could help explain the blood clots associated with COVID-19. They could also explain “why some people have strokes, and why some people have issues in other parts of the body,” Manor said. “The commonality between them is that they all have vascular underpinnings.”

Cancer screenings in U.S. plummeted during pandemic

Nearly 10 million screenings for three common cancers were missed in the U.S. because of the COVID-19 pandemic, a new study suggests. Researchers who compared monthly spring and summer screening rates in 2020 to rates in 2018 and 2019 found a 90.8% decline in breast cancer screening, a 79.3% decline in colorectal cancer screening and a 63.4% decline in prostate cancer screening just in the month of April 2020, researchers reported on Thursday in JAMA Oncology. “There was a deficit of 9.4 million in screening for the three major cancers across the United States that was most likely related to the COVID-19 pandemic,” said coauthor Dr. Ronald Chen of the University of Kansas Cancer Center in Kansas City. “This is a deficit we have to make up for in 2021.” One bit of good news from the study: telehealth visits seemed to be associated with getting cancer screenings back on track. Healthcare teams that could reach patients through telehealth “were able to come up with a plan for screening,” Chen said. “This emphasizes the importance of telehealth and the importance of continuing it after the pandemic is over.”

(Reporting by Nancy Lapid and Linda Carroll; Editing by Bill Berkrot)